Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5202553 | 0.97 | NOS2 (1.00) | NOS2FAAH | |
| SCHEMBL5205627 | 0.84 | NOS2 (0.75) | NOS2 | |
| SCHEMBL5202030 | 0.81 | NOS2 (0.72) | NOS2FAAH | |
| SCHEMBL5202294 | 0.78 | NOS2 (1.00) | NOS2 | |
| SCHEMBL5201831 | 0.78 | NOS2 (1.00) | NOS2 | |
| SCHEMBL5201861 | 0.78 | NOS2 (1.00) | NOS2 | |
| SCHEMBL5203041 | 0.76 | NOS2 (0.90) | NOS2 | |
| SCHEMBL5203317 | 0.76 | NOS2 (0.90) | NOS2 | |
| SCHEMBL5203057 | 0.76 | NOS2 (0.90) | NOS2 | |
| SCHEMBL5206219 | 0.76 | NOS2 (0.95) | NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501504-B1 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AS NOS INHIBITORS | SCHERING AG (DE) | 2007-02-07 | — | — | EP | claimed |
| US-6982259-B2 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-01-03 | — | — | US | claimed |
| EP-1501504-A1 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AS NOS INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-02 | — | — | EP | claimed |
| US-20040023950-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-02-05 | — | — | US | claimed |
| WO-2003092678-A1 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AS NOS INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-11-13 | — | — | WO | claimed |
| EP-1795192-A2 | 1-Substituted imidazole derivatives as nos inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-06-13 | — | — | EP | disclosed |
| US-7202263-B2 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-04-10 | — | — | US | disclosed |
| EP-1501504-B1 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AS NOS INHIBITORS | SCHERING AG (DE) | 2007-02-07 | — | — | EP | disclosed |
| US-20060094725-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| US-6982259-B2 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-01-03 | — | — | US | disclosed |
| EP-1501504-A1 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AS NOS INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-02 | — | — | EP | disclosed |
| US-20040023950-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-02-05 | — | — | US | disclosed |
| WO-2003092678-A1 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AS NOS INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094725-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885FAAH 1536/4885 |
| US-20040023950-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885FAAH 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.